Chenthamarakshan Vasu, PhD
University of Illinois, Chicago
2011 New Treatments
Current therapies for lupus are largely ineffective and pose an increased risk for serious complications such as infections.
Considering that people with the disease produce abnormal antibodies that target tissues and organs within the body, a more effective treatment approach might involve inactivating cells that produce (or help produce) these antibodies (nuclear antigen specific self-reactive B and T cells)—but without altering the ability of the immune system to respond to infections.
Dr. Vasu and colleagues have designed a novel approach to generate production of a large number of the kind of cell that might just be able to pull off this feat: nuclear antigen specific suppressor cells. These suppressor cells are expected to have the ability of selectively inactivating nuclear antigen specific T and B cells, but not immune cells that are against pathogens.
With LRI funding, the team will now test the viability of this strategy for preventing and treating lupus using a mouse model.
Revised April 2011
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms
- B Cells
- Cardiovascular System
- Cell Signaling
- Central Nervous System
- Dendritic Cells
- Environmental Triggers
- Gender Matters
- General Immune System Function
- Human Lupus Biology
- Lupus Pregnancy
- New to Lupus
- New Treatments
- T Cells
- Target Identification
- Why the Lupus Immune System Reacts to Its Own DNA